<DOC>
	<DOCNO>NCT03002779</DOCNO>
	<brief_summary>The purpose study determine rout excretion JNJ-53718678 metabolite , explore metabolic pathway JNJ-53718678 , determine chemical structure predominant metabolites healthy adult male participant single oral dose 500 milligram ( mg ) 14C-JNJ-53718678 .</brief_summary>
	<brief_title>A Study Characterize Absorption , Metabolism , Excretion 14C-JNJ-53718678 After Single Oral Dose Healthy Male Participants</brief_title>
	<detailed_description />
	<criteria>A male participant : ) Must sexually abstinent ( defined refrain sexual intercourse Day 1 ( day dose ) 90 day study drug administration ) , OR b ) Who sexually active ( either heterosexual , include pregnant woman , homosexual ) must agree use barrier method contraception ( eg , condom ) Day 1 ( day dose ) 90 day study drug administration , AND c ) Who sexually active woman childbearing potential must agree use barrier method contraception ( eg , condom ) Day 1 ( day dose ) 90 day study drug administration , conjunction female partner use highly effective contraceptive ( implantable progestogenonly hormone contraception associate inhibition ovulation ; intrauterine device ; intrauterine hormonereleasing system , combine [ estrogen progestogen contain ] hormonal contraception associate inhibition ovulation : oral , intravaginal , transdermal ; progestogenonly hormone contraception associate inhibition ovulation : oral injectable ) ) Must agree donate sperm Day 1 ( day dose ) 90 day study drug administration Participant must body mass index ( BMI ; weight kg divide square height meter ) 18.0 30.0 kilogram per square meter ( kg/m^2 ) Participant must blood pressure ( participant supine 5 minute ) 90 140 millimeter mercury ( mmHg ) systolic , inclusive , high 90 mmHg diastolic Participant must normal 12lead electrocardiogram ( ECG ) ( base mean value triplicate ECG parameter ) , consistent normal cardiac conduction function screening , include : ) normal sinus rhythm ( heart rate 45 90 beat per minute ( bpm ) , extremes include ) ; b ) mean QT interval correct heart rate accord Fridericia formula ( QTcF ) interval less equal ( &lt; = ) 450 millisecond ( m ) ; c ) mean QRS interval &lt; 110 m ; ) mean PR interval &lt; 200 m ; e ) morphology consistent healthy cardiac conduction function Participants must healthy basis medical evaluation reveals absence clinically relevant abnormality include physical examination ( include height body weight measurement skin examination ) , medical history , vital sign ( systolic diastolic blood pressure , pulse rate , orthostatic blood pressure change , respiratory rate , body temperature ) , creatinine clearance ( 60 milliliter per minute ( mL/min ) screen use CockroftGault equation ) , result blood biochemistry , blood coagulation , hematology test , urinalysis perform screening , Day 1 , predose Day 1 , whichever applicable . If abnormality , exception describe exclusion criterion , participant may include investigator judge abnormalities deviation normal clinically significant . This determination must record participant 's source document initial investigator Participants remove gallbladder , history upper gastrointestinal ( stomach , duodenum ) surgery , recent ( less 3 month prior screen ) episode gallbladder stone Participants history heart arrhythmia ( extrasystole , tachycardia rest ) history risk factor Torsade de Pointes syndrome ( example , hypokalemia , family history long QT syndrome ) Participant intolerance xylocaine , lactose , midazolam Participant history hepatitis A antibody immunoglobulin M ( IgM ) , hepatitis B virus surface antigen ( HBsAg ) , hepatitis C virus antibody ( antiHCV ) positive , clinically active liver disease , test positive hepatitis A antibody IgM , HBsAg anti HCV screen Participant history human immunodeficiency virus ( HIV ) antibody positive , test positive HIV screening</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>